Literature DB >> 12016635

An ovine model of tachycardia-induced degenerative dilated cardiomyopathy and heart failure with prolonged onset.

Melissa J Byrne1, Jai S Raman, Clif A Alferness, Murry D Esler, David M Kaye, John M Power.   

Abstract

BACKGROUND: The aim of this study was to develop a model of long-term progressive heart failure (HF). METHODS AND
RESULTS: A cardiac output flowprobe was implanted on the pulmonary artery of 9 adult sheep weighing 40 to 50 kg. Rapid ventricular pacing for 21 days at 160 to 190 bpm (rate A) resulted in moderate HF. Animals were then paced at 205 to 215 bpm (rate B) for 42 days (severe HF) and for 28 days at rate B (advanced HF). Data were collected at baseline and moderate, severe, and advanced HF during submaximal exercise testing and by transthoracic echocardiography in sinus rhythm. There were marked increases in left ventricular (LV) area, mitral valve regurgitation, and LV end-diastolic pressure and decreases in LV wall thickness, LV ejection fraction, positive and negative dP/dt(max), and positive (dP/dt(max))/P throughout the pacing protocol.
CONCLUSIONS: This ovine HF model incorporates the progressive nature of human HF and allows examination of both structural changes and hemodynamic parameters of HF during and after exercise challenge.

Entities:  

Mesh:

Year:  2002        PMID: 12016635     DOI: 10.1054/jcaf.2002.32323

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  9 in total

Review 1.  Model-specific selection of molecular targets for heart failure gene therapy.

Authors:  Michael G Katz; Anthony S Fargnoli; Catherine E Tomasulo; Louella A Pritchette; Charles R Bridges
Journal:  J Gene Med       Date:  2011-10       Impact factor: 4.565

2.  Efficacy of the Acorn Cardiac Support Device in animals with heart failure secondary to high rate pacing.

Authors:  John M Power; Jai Raman; Melissa J Byrne; Clif A Alferness
Journal:  Heart Fail Rev       Date:  2005-06       Impact factor: 4.214

Review 3.  Atrial fibrillation and heart failure: cause or effect?

Authors:  Christina Luong; Marion E Barnes; Teresa S M Tsang
Journal:  Curr Heart Fail Rep       Date:  2014-12

Review 4.  The effects of heart rate control in chronic heart failure with reduced ejection fraction.

Authors:  Dario Grande; Massimo Iacoviello; Nadia Aspromonte
Journal:  Heart Fail Rev       Date:  2018-07       Impact factor: 4.214

5.  Sheep can be used as animal model of regional myocardial remodeling and controllable work.

Authors:  Jürgen Duchenne; Piet Claus; Efstathios D Pagourelias; Razvan O Mada; Joeri Van Puyvelde; Kathleen Vunckx; Eric Verbeken; Olivier Gheysens; Filip Rega; Jens-Uwe Voigt
Journal:  Cardiol J       Date:  2018-03-23       Impact factor: 2.737

6.  Chronic high-rate pacing induces heart failure with preserved ejection fraction-like phenotype in Ossabaw swine.

Authors:  Johnathan D Tune; Adam G Goodwill; Hana E Baker; Gregory M Dick; Cooper M Warne; Selina M Tucker; Salman I Essajee; Chastidy A Bailey; Jessica A Klasing; Jacob J Russell; Patricia E McCallinhart; Aaron J Trask; Shawn B Bender
Journal:  Basic Res Cardiol       Date:  2022-10-12       Impact factor: 12.416

7.  Reversal of cardiomyopathy in patients with congestive heart failure secondary to tachycardia.

Authors:  Zhao Donghua; Peng Jian; Xiao Zhongbo; Zhang Feifei; Peng Xinhui; Yang Hao; Liu Fuqiang; Li Yan; Xie Yong; Huang Xinfu; Meng Surong; Wu Muli; Xu Dingli
Journal:  J Interv Card Electrophysiol       Date:  2012-10-23       Impact factor: 1.900

8.  No contribution of IP3-R(2) to disease phenotype in models of dilated cardiomyopathy or pressure overload hypertrophy.

Authors:  Nicola Cooley; Kunfu Ouyang; Julie R McMullen; Helen Kiriazis; Farah Sheikh; Wei Wu; Yongxin Mu; Xiao-Jun Du; Ju Chen; Elizabeth A Woodcock
Journal:  Circ Heart Fail       Date:  2012-12-20       Impact factor: 8.790

Review 9.  Small and large animal models in cardiac contraction research: advantages and disadvantages.

Authors:  Nima Milani-Nejad; Paul M L Janssen
Journal:  Pharmacol Ther       Date:  2013-10-15       Impact factor: 12.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.